MarketPulse

royalties

6 articles
BenzingaBenzinga··Na

Royalty Pharma Maintains Dividend Momentum With $0.235 Q2 Payout

Royalty Pharma declares $0.235 per share dividend for Q2 2026, reinforcing its cash-generative business model across 35+ pharmaceutical products.
RPRXdividendshareholder returns
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aligos Scores $25M Upfront in China Deal for Hepatitis B Drug

Aligos Therapeutics licenses pevifoscorvir to Xiamen Amoytop for Greater China development, receiving $25M upfront and up to $420M in milestones.
ALGSclinical developmentpevifoscorvir sodium
BenzingaBenzinga··Not Specified

Eli Lilly's Centessa Acquisition Validates Nxera's Drug Discovery Platform

Eli Lilly acquires Centessa Pharmaceuticals, which developed sleep-disorder treatments with Nxera Pharma. Nxera retains royalties, milestones, and equity stake.
LLYCNTAacquisitiondrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Eli Lilly Acquires Centessa Pharmaceuticals in Sleep-Wake Drug Push

Eli Lilly acquires Centessa Pharmaceuticals, developer of OX2R agonists for sleep disorders co-created with Nxera Pharma, which retains milestone payments and royalties.
LLYCNTAacquisitiondrug discovery
The Motley FoolThe Motley Fool··Rick Orford

Arm Holdings Positioned to Capitalize on Edge AI Boom, But Valuation Concerns Linger

Arm Holdings positioned to benefit from edge AI trend through higher royalties per chip, but premium valuation warrants cautious investor approach.
ARMvaluationedge AI
BenzingaBenzinga··Lekha Gupta

Fusion Fuel Diversifies Into Nuclear Energy With Royal Uranium Deal

Fusion Fuel acquires controlling stake in Royal Uranium, gaining 16 uranium royalties to capitalize on growing nuclear energy demand. Stock fell 3.43% on announcement.
HTOOclean energyenergy demand